REG - Oxford BioDynamics - Notice of FY22 Results and Investor Webinar

Oxford BiodynamicsAnnouncement

21/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221221:nRSU2385Ka&default-theme=true

RNS Number : 2385K  Oxford BioDynamics PLC  21 December 2022

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Notice of Results and Investor Webinar

21 December 2022 - Oxford BioDynamics Plc (AIM: OBD, the Company), a
biotechnology company developing precision medicine tests for immune health
based on the EpiSwitch® 3D genomics platform expects to announce its results
for the year ended 30 September 2022 on Tuesday 24 January 2023.

Following release of the results, the Company's management team will conduct a
live presentation via the Yellowstone Advisory webinar platform to investors,
at 2pm GMT on Tuesday 24 January 2023.

The online presentation is open to both existing and potential shareholders.
 Questions will be addressed at the end of the presentation and may be
submitted either before the presentation by emailing
info@yellowstoneadvisory.com (mailto:info@yellowstoneadvisory.com) or during
the presentation.

To register for the presentation, please visit:
https://us02web.zoom.us/webinar/register/8016711901502/WN_BdNuLMzhT8KBzPJUHHEvng
(https://us02web.zoom.us/webinar/register/8016711901502/WN_BdNuLMzhT8KBzPJUHHEvng)

-Ends-

 

For further details please contact:

 

 Oxford BioDynamics Plc                             Tel: +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital - Nominated Adviser and Broker       Tel: +44 (0)20 7408 4090

 Advisory: Stephane Auton / John More

 Broking: Fiona Conroy

 Instinctif Partners                                Tel: +44 (0)20 7457 2020

 Melanie Toyne-Sewell / Rozi Morris / Adam Loudon   OxfordBioDynamics@instinctif.com

 

Notes for Editors

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (https://www.mycirt.com/)
 (Checkpoint Inhibitor Response Test) for cancer, a predictive immune
response profile for immuno-oncology (IO) checkpoint inhibitor treatments,
launched in February 2022.

In March 2021, the Company launched its first commercial prognostic
test, EpiSwitch (https://covidseveritytest.com/) ®
(https://covidseveritytest.com/)  CST (https://covidseveritytest.com/)
 (Covid Severity Test) and the first commercially available microarray kit
for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit (http://store.oxfordbiodynamics.com/) .

The Company has developed a proprietary 3D genomic biomarker platform,
EpiSwitch®, which can build molecular diagnostic classifiers for prediction
of response to therapy, patient prognosis, disease diagnosis and subtyping,
and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg, MD, USA and a
reference laboratory in Penang, Malaysia.

For more information, please visit the Company's
website, www.oxfordbiodynamics.com (https://www.oxfordbiodynamics.com/) , or
follow on Twitter (https://twitter.com/OxBioDynamics)  or LinkedIn
(https://www.linkedin.com/company/oxford-biodynamics/) .

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 10,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcome, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUKVKRUUUUAAA